P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
Heinz Ludwig,Michel Delforge,Thierry Facon,Hermann Einsele,Philippe Moreau,Hervé Avet-Loiseau,Mario Boccadoro,Roman Hájek,Mohamad Mohty,Michele Cavo,Meletios A. Dimopoulos,Jesús F. San-Miguel,Evangelos Terpos,Sonja Zweegman,Laurent Garderet,Maria-Victoria Mateos,Gordon Cook,Xavier Leleu,Hartmut Goldschmidt,Graham Jackson,Martin Kaiser,Katja Weisel,Niels W.C.J. van de Donk,Anders Waage,Meral Beksac,Ulf H. Mellqvist,Monika Engelhardt,Jo Caers,Christoph Driessen,Joan Bladé,Pieter Sonneveld +30 more
TL;DR: In this review, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome and present with very specific side effect profiles.
Journal ArticleDOI
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis
Graham Jackson,Laura Rosiñol,Sarah A. Holstein,Philippe Moreau,Stefano Spada,Faith E. Davies,Juan José Lahuerta,Xavier Leleu,Sara Bringhen,Andrea Evangelista,Cyrille Hulin,Ugo Panzani,David A Cairns,Francesco Di Raimondo,Margaret Macro,Anna Marina Liberati,Charlotte Pawlyn,Massimo Offidani,Andrew Spencer,Roman Hájek,Evangelos Terpos,Gareth J. Morgan,Joan Bladé,Pieter Sonneveld,Jesús F. San-Miguel,Philip L. McCarthy,Heinz Ludwig,Mario Boccadoro,Maria-Victoria Mateos,Michel Attal +29 more
TL;DR: Based on PFS and OS results of this NMA, lenalidomide maintenance appears to be the best treatment option, by synthesizing the available evidence of novel agent-based maintenance in the past 20 years.
Journal ArticleDOI
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.
Emmanuelle Ménoret,Patricia Gomez-Bougie,Alexandrine Geffroy-Luseau,Sylvanne Daniels,Philippe Moreau,Steven Le Gouill,Jean-Luc Harousseau,Régis Bataille,Martine Amiot,Catherine Pellat-Deceunynck +9 more
TL;DR: The data clearly encourage clinical trials of anti-TRAILR1 mAb in multiple myeloma, especially for patients whose disease is in relapse, at the time of drug resistance.
Journal ArticleDOI
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Thierry Guillaume,Florent Malard,Leonardo Magro,Myriam Labopin,Reza Tabrizi,Cécile Borel,Patrice Chevallier,Stephane Vigouroux,Pierre Peterlin,Alice Garnier,Marie-Thérèse Rubio,Anne Huynh,Noel Milpied,Philippe Moreau,Béatrice Gaugler,Ibrahim Yakoub-Agha,Mohamad Mohty +16 more
TL;DR: It is confirmed that AZA is well tolerated as a prophylactic treatment to reduce the risk of post-Transplantation relapse and compared favorably to those of patients who receive no post-transplant maintenance.
Journal ArticleDOI
Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.
Raphael Carapito,Nicolas Jung,Nicolas Jung,Marius Kwemou,Marius Kwemou,Meiggie Untrau,Meiggie Untrau,Sandra Michel,Angélique Pichot,Angélique Pichot,Gaëlle Giacometti,Cécile Macquin,Cécile Macquin,Wassila Ilias,Wassila Ilias,Aurore Morlon,Irina Kotova,Petya Apostolova,Annette Schmitt-Graeff,Anne Cesbron,Katia Gagne,Machteld Oudshoorn,Bronno van der Holt,Myriam Labalette,Eric Spierings,Christophe Picard,Pascale Loiseau,Pascale Loiseau,Ryad Tamouza,Ryad Tamouza,Antoine Toubert,Antoine Toubert,A. Parissiadis,Valérie Dubois,Xavier Lafarge,Myriam Maumy-Bertrand,Frédéric Bertrand,Luca Vago,Fabio Ciceri,Catherine Paillard,Sergi Querol,Jorge Sierra,Katharina Fleischhauer,Arnon Nagler,Myriam Labopin,Hidetoshi Inoko,Hidetoshi Inoko,Peter A. von dem Borne,Jürgen Kuball,Masao Ota,Masao Ota,Yoshihiko Katsuyama,Yoshihiko Katsuyama,Mauricette Michallet,Bruno Lioure,Régis Peffault de Latour,Didier Blaise,Jan J. Cornelissen,Ibrahim Yakoub-Agha,Frans H.J. Claas,Philippe Moreau,Noel Milpied,Dominique Charron,Dominique Charron,Mohamad Mohty,Robert Zeiser,Gérard Socié,Seiamak Bahram +67 more
TL;DR: The tight linkage disequilibrium between MICA and HLA-B renders identifying a MICA-matched donor readily feasible in clinical practice and significantly influences key clinical outcomes of HCT in which a marked reduction of GVHD is paramount.